MRKR MARKER THERAPEUTICS INC Product Launches 8-K Filing 2025 - New Product Launches On May 20, 2025, Marker Therapeutics, Inc. announced that data from their Phase 1 study of MT-601 shows lymphodepletion enhances the growth and persistence of specialized T-cells in lymphoma patients.Get access to all SEC 8-K filings of the MARKER THERAPEUTICS INC